Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44,162,869
-
Total 13F shares
-
33,322,061
-
Share change
-
+33,322,061
-
Total reported value
-
$999,836,330
-
Price per share
-
$30.13
-
Number of holders
-
38
-
Value change
-
+$999,835,543
-
Number of buys
-
38
Institutional Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q3 2020
As of 30 Sep 2020,
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) was held by
38 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,322,061 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, BAKER BROS. ADVISORS LP, FMR LLC, HILLHOUSE CAPITAL ADVISORS, LTD., UBS ASSET MANAGEMENT AMERICAS INC, MASSACHUSETTS FINANCIAL SERVICES CO /MA/, PRICE T ROWE ASSOCIATES INC /MD/, Rock Springs Capital Management LP, SUVRETTA CAPITAL MANAGEMENT, LLC, and MILLENNIUM MANAGEMENT LLC.
This page lists
38
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.